Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Erlotinib in front-line treatment of non-small cell lung cancer. A phase II study

Erlotinib in front-line treatment of non-small cell lung cancer. A phase II study. Clinical Cancer Research. 2006; 20(12):6049-6055.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.